| Full text | |
| Author(s): |
Loch, Alexandre A.
[1]
;
Zanetti, Marcus V.
[2, 3, 1]
;
de Sousa, Rafael T.
[1]
;
Chaim, Tiffany M.
[3]
;
Serpa, Mauricio H.
[3]
;
Gattaz, Wagner F.
[2, 1]
;
Teixeira, Antonio L.
[4]
;
Machado-Vieira, Rodrigo
[2, 1, 5]
Total Authors: 8
|
| Affiliation: | [1] Univ Sao Paulo, Dept & Inst Psychiat, Lab Neurosci, LIM 27, Sao Paulo - Brazil
[2] Univ Sao Paulo, Ctr Interdisciplinary Res Appl Neurosci NAPNA, Sao Paulo - Brazil
[3] Univ Sao Paulo, Dept & Inst Psychiat, Lab Psychiat Neuroimaging, LIM 21, Sao Paulo - Brazil
[4] Fac Med Minas Gerais, Interdisciplinary Lab Med Invest, Belo Horizonte, MG - Brazil
[5] NIMH, ETPB, NIH, Bethesda, MD - USA
Total Affiliations: 5
|
| Document type: | Journal article |
| Source: | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY; v. 56, p. 243-246, JAN 2 2015. |
| Web of Science Citations: | 11 |
| Abstract | |
Background: Bipolar disorder (BD) has been associated with diverse abnormalities in neural plasticity and cellular resilience. Neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5) support synaptic neuronal survival and differentiation. NT-3 and NT-4/5 levels were found to be altered in BD, potentially representing a physiological response against cellular stress. However, the use of psychopharmacological agents and heterogeneous mood states may constitute important biases in such studies. Thus, we aimed to assess NT-3 and NT-4/5 levels in medication-free BD type I or II individuals in a current depressive episode, before and after 6weeks of lithium monotherapy and matched with healthy controls. Methods: Twenty-three patients with BD type I or II during a depressive episode and 28 healthy controls were studied. Patients were required to have a 21-item Hamilton Depression Rating Scale score >= 18 and had not undergone any psychopharmacological treatment for at least 6 weeks prior to study entry. Patients were treated with lithium for 6 weeks and plasma NT-3 and NT-4/5 levels were determined at baseline and end point using ELISA method. Results: Baseline plasma levels of both NT-3 and NT-4/5 were significantly increased in acutely depressed BD subjects in comparison to healthy controls (p = 0.040 and 0.039, respectively). The NT-3 and NT-4/5 levels did not significantly change after lithium treatment. NT-3 and NT-4/5 levels were positively correlated to illness duration in BD (p = 0.032 and 0.034, respectively). Conclusion: Our findings suggest that NT-3 and NT-4/5 levels are increased in the depressive phase of BD, which seems directly associated with illness duration. The increased levels of NT-3 and NT-4/5 may underlie a biological response to cellular stress associated with the course of BD. (C) 2014 Elsevier Inc. All rights reserved. (AU) | |
| FAPESP's process: | 13/03905-4 - NEUROBIOLOGICAL DIFFERENCES BETWEEN TREATMENT-NAIVE PATIENTS WITH BIPOLAR DISORDER SUBTYPES I AND II |
| Grantee: | Marcus Vinicius Zanetti |
| Support Opportunities: | Scholarships in Brazil - Post-Doctoral |
| FAPESP's process: | 09/14891-9 - Longitudinal study on the neuroprotective and neurotrophic effects of lithium in bipolar disorder: identification of cellular and molecular targets clinically relevant |
| Grantee: | Rodrigo Machado-Vieira |
| Support Opportunities: | Research Grants - Young Investigators Grants |